https://imedic.health/en/health/news/glp1-discontinuation-heart-risk-type-2-diabetes iMedic en 2026-07-04 GLP-1 Discontinuation and Heart Risk in Type 2 Diabetes https://imedic.health/en/health/news/pediatric-formulations-japan-pmda-child-medicine-access iMedic en 2026-07-04 Pediatric Formulations and Child Medicine Access: Japan PMDA Plan Explained https://imedic.health/en/health/news/alzheimers-tau-spread-protein-packages-treatment-target iMedic en 2026-07-04 Alzheimer's Tau Spread: Protein Packages May Reveal a New Treatment Target https://imedic.health/en/health/news/enlarged-left-atrium-stroke-cause-research iMedic en 2026-07-04 Enlarged Left Atrium and Stroke Risk: Why Heart Structure May Matter https://imedic.health/en/health/news/glp1-longevity-heart-kidney-trial-evidence iMedic en 2026-07-05 GLP-1 Longevity Claims: What Heart and Kidney Trial Evidence Shows https://imedic.health/en/health/news/statins-antihypertensives-obesity-heart-risk-gap iMedic en 2026-07-05 Statins and Blood Pressure Drugs Narrow Obesity Heart Risk Gap https://imedic.health/en/health/news/medicare-glp1-bridge-obesity-drug-coverage iMedic en 2026-07-05 Medicare GLP-1 Bridge Program Expands Access to Obesity Medicines https://imedic.health/en/health/news/glp1-medicare-weight-loss-safety-monitoring-older-adults iMedic en 2026-07-06 GLP-1 Weight-Loss Drugs and Medicare: Safety Monitoring for Older Adults